AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05739539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: spectral domain optical coherence tomography
Description: optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
Study NCT05802771 — intervention group
Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection of the lung cancer
Study NCT05334459 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~  o ER / PR /Her2 /Ki67 study)~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice.
Study NCT05874310 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-002
Description: Comparison of different dosages of FT-002
Study NCT05768399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The level of biomarkers in Peripheral blood
Description: All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
Study NCT05474547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Students will meditate for 30 min every day for 10 days
Study NCT04594733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Description: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Study NCT04594733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Description: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Study NCT04970407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Intramuscular Injection, concentration 300 units (U)
Study NCT04970407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Intramuscular Injection, concentration 50 U
Study NCT04938596 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Respiratory bundle
Description: * Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~* Promotion of strategies to improve house ventilation during 2 weeks~* Provision of a TB leaflet and nurse education about TB transmission.
Study NCT06333483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obecabtagene autoleucel (obe-cel)
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
Study NCT05365334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity exercise session
Description: subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
Study NCT05365334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise session
Description: subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
Study NCT05365334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise session
Description: subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
Study NCT05475834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417
Description: Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
Study NCT04163926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group cataract follow up
Description: Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
Study NCT04163926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care consultant follow up
Description: Usual care group - Consultant led post op follow up
Study NCT06186596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triamcinolone delivered via injection assistance device
Description: 0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
Study NCT05298436 — intervention group
Intervention type: OTHER
Intervention: Follow-up interview
Description: All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
Study NCT05709405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading intervention
Description: The intervention will use a reading program called Lesing for alle (Reading for all) based on the research of Accessible Literacy Learning (ALL) which is an evidence-based approach, designed to teach reading skills to students with various intellectual disabilities, including autism spectrum disorders
Study NCT06077435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: AI system
Study NCT05172882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound site infiltration
Description: Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
Study NCT05172882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block
Description: External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
Study NCT05372679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: The TIVUS system will be used for renal denervation
Study NCT05716529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation protocol
Description: It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
Study NCT05716529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation protocol
Description: It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
Study NCT04443959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMAS
Description: Treatment consists of 6 weekly telemedicine sessions during pregnancy.
Study NCT06485336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Each tablet will be taken once daily for 84 days.
Study NCT06485336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each tablet will be taken once daily for 84 days.
Study NCT06171022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry seed pillow
Description: 4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
Study NCT06171022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
Study NCT05015725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of life assessment, biochemical measures
Description: Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to \~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels.
Study NCT04871347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-101
Description: IV infusion
Study NCT06342479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Education
Description: Discharge education will be provided.
Study NCT04342013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support Application
Description: Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
Study NCT05194241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One MORE
Description: One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
Study NCT05834920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (TPS)
Description: Participants will be treated with the TPS device NEUROLITH (Storz Medical AG). Treatments will be administered for up to 12 sessions within 4 weeks, each session consisting of 6000 TPS pulses of 0.2 mJ/mm².
Study NCT05834920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Participants will engage in a neurofeedback game designed to increase the ratio of theta/beta frequency bands in electroencephalography measurement. This intervention will be delivered for up to 12 sessions within 4 weeks.
Study NCT05171205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
Study NCT06391437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Extraction of blood sample
Description: Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.
Study NCT05643209 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ablation
Description: epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
Study NCT06174545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pigment Solution Program
Description: adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
Study NCT06227065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions
Study NCT06227065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation.
Study NCT06227065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7.
Study NCT05132413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
Description: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
Study NCT05132413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
Description: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
Study NCT05132413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Description: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Study NCT04968522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
Study NCT04968522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
Study NCT04968522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
Study NCT04968522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride 18 MG
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
Study NCT04968522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulfate
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
Study NCT05212779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Signatera testing
Description: 26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
Study NCT05212779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Altera Testing
Description: 6ml blood and tissue sample.
Study NCT04928807 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Short course radiotherapy sequential camrelizumab and chemotherapy
Description: Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
Study NCT04928807 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy sequential camrelizumab and chemotherapy
Description: Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
Study NCT05205109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-037
Description: Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1.
Study NCT05205109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA ®( Pembrolizumab)
Description: Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1.
Study NCT05364580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROTOXIN
Description: Botulinum toxin Type A
Study NCT05364580 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Botulinum toxin Type A
Study NCT04419805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Palatal TAD
Description: A single mini-screw inserted in the mid-palate
Study NCT04419805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two buccal TADs
Description: Two buccal TADs inserted in the upper jaw
Study NCT06484374 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Robot-assisted minimally invasive treatment
Description: An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
Study NCT06484374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive treatment
Description: An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
Study NCT05221138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116
Description: VV116 oral tablets, 400mg
Study NCT06276400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion valence
Description: Positive vs. Negative (temporally extended sequence)
Study NCT06276400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time
Description: ∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)